Kilitch Drugs (India) Limited Share Price & Analysis
₹214.97+3.59%Updated 28 Oct 2026, 03:30 pm IST
LTP
₹214.97+3.59%Open
₹211.05High
₹223.80Low
₹206.10Close
₹214.9752W High
₹267.9052W Low
₹117.00Volume
72KLot Size
1Sector
HealthcareMarket Cap
₹764 CrFace Value
₹10Small Cap
Price Chart
Candle
Range
Fundamentals
P/E
25.40Sector P/E
50.20P/B
—EPS
₹7.45ROE
10.60%ROCE
13.40%D/E Ratio
0.32Div Yield
0.00%Book Value
₹80.00Strengths
- Attractively valued vs sector (P/E 25.4x vs industry 50.2x)
- Low debt relative to equity (D/E 0.3x)
Concerns
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,758 | ₹4.2L Cr | 33.2 | 5.05 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,559 | ₹2.4L Cr | 79.8 | 15.15 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,557 | ₹1.7L Cr | 79.3 | 9.43 | 27.4 | 15.2 | 0.77 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,176 | ₹1.1L Cr | 23.1 | 4.37 | 21.2 | 21.1 | 0.38 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,137 | ₹1.1L Cr | 52.8 | 12.35 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,366 | ₹1.1L Cr | 30.2 | 3.21 | 11.6 | 15.5 | 0.01 |
| LAURUSLABS Laurus Labs Limited | ₹2,182 | ₹1.1L Cr | 97.4 | 22.22 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
KILITCH · as of Jun 2026
Promoters69.23%
Public30.77%
| Category | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 69.23% | 69.23% | 69.23% | 69.23% | 69.23% | 69.23% |
| Public | 30.77% | 30.77% | 30.77% | 30.76% | 30.77% | 30.77% |
Corporate Events
To consider and approve the financial results for the period ended March 31, 2026
Results14 May 2026
Bonus 1:1
Bonus23 Mar 2026
Rights 2:23 @ Premium Rs 347/-
Rights14 Jul 2025
Annual General Meeting
AGM18 Sept 2024
Annual General Meeting
AGM20 Sept 2023
Latest News
All newsKilitch to divest entire stake in Ethiopian subsidiary KEB
*Kilitch to divest entire stake in Ethiopian subsidiary KEB* — Kilitch Drugs announced the disinvestment of its entire stake in KEB, its Ethiopian subsidiary, via a press release dated October 23, 2026. The move signals a strategic exit from international operations. Financial details of the divestment were not disclosed. 📊 *STOCKS:* KILITCH | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Divestment
NSE Filing5d ago
Kilitch Drugs shows strong earnings but underlying issues persist
*Kilitch Drugs (India)'s healthy earnings may be misleading due to one-time gains and declining core margins.* Revenue grew by **12% YoY**, but operating profit growth was only **4%**, indicating cost pressures. Debt levels remain elevated at **₹320 crore**, raising concerns over sustainability. 📊 *STOCKS:* KILITCH | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Earnings
simplywall.st27 May
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹54 Cr 10.2% | ₹49 Cr 14.0% | ₹43 Cr 29.5% | ₹61 Cr 8.9% | ₹56 Cr 19.1% | ₹47 Cr 42.4% | ₹33 Cr 26.4% | ₹44.82 Cr |
| Op. Profit | ₹6 Cr 20.0% | ₹5 Cr 66.7% | ₹3 Cr 80.0% | ₹15 Cr 66.7% | ₹9 Cr 50.0% | ₹6 Cr 200.0% | ₹2 Cr 71.8% | ₹7.08 Cr |
| OPM | 11.0% 10.0% | 10.0% 25.0% | 8.0% 66.7% | 24.0% 50.0% | 16.0% 23.1% | 13.0% 160.0% | 5.0% 68.4% | 15.8% |
| Net Profit | ₹4 Cr 50.0% | ₹8 Cr 300.0% | ₹2 Cr 80.0% | ₹10 Cr 66.7% | ₹6 Cr 33.3% | ₹9 Cr | ₹0 Cr 100.0% | ₹3.68 Cr |
| EPS (₹) | 1.27 45.7% | 2.34 169.0% | 0.87 70.7% | 2.97 74.7% | 1.7 30.9% | 2.46 547.4% | 0.38 63.1% | 1.03 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹235 Cr 18.7% | ₹198 Cr 28.6% | ₹154 Cr 10.0% | ₹140 Cr 22.8% | ₹114 Cr 67.6% | ₹68 Cr 28.3% | ₹53 Cr 35.4% | ₹82 Cr 60.8% | ₹51 Cr 88.9% | ₹27 Cr |
| Expenses | ₹199 Cr 19.2% | ₹167 Cr 28.5% | ₹130 Cr 6.6% | ₹122 Cr 17.3% | ₹104 Cr 65.1% | ₹63 Cr 18.9% | ₹53 Cr 29.3% | ₹75 Cr 66.7% | ₹45 Cr 60.7% | ₹28 Cr |
| Op. Profit | ₹37 Cr 15.6% | ₹32 Cr 33.3% | ₹24 Cr 33.3% | ₹18 Cr 80.0% | ₹10 Cr 100.0% | ₹5 Cr | ₹0 Cr 100.0% | ₹7 Cr 16.7% | ₹6 Cr 700.0% | ₹-1 Cr |
| OPM | 16.0% 0.0% | 16.0% 0.0% | 16.0% 23.1% | 13.0% 44.4% | 9.0% 12.5% | 8.0% 700.0% | 1.0% 88.9% | 9.0% 18.2% | 11.0% 650.0% | -2.0% |
| Other Income | ₹11 Cr 0.0% | ₹11 Cr 175.0% | ₹4 Cr 33.3% | ₹3 Cr 0.0% | ₹3 Cr 0.0% | ₹3 Cr 25.0% | ₹4 Cr 0.0% | ₹4 Cr 33.3% | ₹3 Cr 200.0% | ₹1 Cr |
| Interest | ₹6 Cr 20.0% | ₹5 Cr 16.7% | ₹6 Cr 20.0% | ₹5 Cr 400.0% | ₹1 Cr 0.0% | ₹1 Cr 0.0% | ₹1 Cr 0.0% | ₹1 Cr | ₹0 Cr | ₹0 Cr |
| Depreciation | ₹4 Cr 33.3% | ₹3 Cr 0.0% | ₹3 Cr 25.0% | ₹4 Cr 100.0% | ₹2 Cr 0.0% | ₹2 Cr 0.0% | ₹2 Cr 0.0% | ₹2 Cr 0.0% | ₹2 Cr 80.0% | ₹10 Cr |
| PBT | ₹39 Cr 14.7% | ₹34 Cr 78.9% | ₹19 Cr 58.3% | ₹12 Cr 20.0% | ₹10 Cr 100.0% | ₹5 Cr 150.0% | ₹2 Cr 77.8% | ₹9 Cr 50.0% | ₹6 Cr 166.7% | ₹-9 Cr |
| Tax % | 24.0% 14.3% | 28.0% 6.7% | 30.0% 3.2% | 31.0% 11.4% | 35.0% 29.6% | 27.0% 43.8% | 48.0% 12.7% | 55.0% 243.8% | 16.0% 420.0% | -5.0% |
| Net Profit | ₹30 Cr 20.0% | ₹25 Cr 78.6% | ₹14 Cr 75.0% | ₹8 Cr 33.3% | ₹6 Cr 50.0% | ₹4 Cr 300.0% | ₹1 Cr 75.0% | ₹4 Cr 20.0% | ₹5 Cr 155.6% | ₹-9 Cr |
| EPS (₹) | 8.63 13.1% | 7.63 83.0% | 4.17 35.4% | 3.08 41.9% | 2.17 99.1% | 1.09 336.0% | 0.25 78.3% | 1.15 33.1% | 1.72 155.7% | -3.09 |
| Div Payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% 100.0% | 20.0% 53.8% | 13.0% | 0.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Liabilities | ||||||||||
| Equity Capital | ₹17 Cr 6.3% | ₹16 Cr 0.0% | ₹16 Cr 0.0% | ₹16 Cr 0.0% | ₹16 Cr 6.7% | ₹15 Cr 0.0% | ₹15 Cr 0.0% | ₹15 Cr 7.1% | ₹14 Cr 7.7% | ₹13 Cr |
| Reserves | ₹248 Cr 33.3% | ₹186 Cr 16.3% | ₹160 Cr 17.6% | ₹136 Cr 9.7% | ₹124 Cr 10.7% | ₹112 Cr 8.7% | ₹103 Cr 2.8% | ₹106 Cr 8.2% | ₹98 Cr 11.4% | ₹88 Cr |
| Borrowings | ₹84 Cr 71.4% | ₹49 Cr 53.1% | ₹32 Cr 45.5% | ₹22 Cr 10.0% | ₹20 Cr 33.3% | ₹15 Cr 15.4% | ₹13 Cr 44.4% | ₹9 Cr 800.0% | ₹1 Cr 0.0% | ₹1 Cr |
| Other Liabilities | ₹49 Cr 19.7% | ₹61 Cr 90.6% | ₹32 Cr 30.4% | ₹46 Cr 8.0% | ₹50 Cr 18.0% | ₹61 Cr 408.3% | ₹12 Cr 7.7% | ₹13 Cr 13.3% | ₹15 Cr 36.4% | ₹11 Cr |
| Total Liabilities | ₹399 Cr 27.5% | ₹313 Cr 30.4% | ₹240 Cr 9.1% | ₹220 Cr 4.8% | ₹210 Cr 3.4% | ₹203 Cr 42.0% | ₹143 Cr 0.7% | ₹144 Cr 12.5% | ₹128 Cr 13.3% | ₹113 Cr |
Assets | ||||||||||
| Fixed Assets | ₹64 Cr 0.0% | ₹64 Cr 3.2% | ₹62 Cr 3.1% | ₹64 Cr 1.5% | ₹65 Cr 116.7% | ₹30 Cr 6.3% | ₹32 Cr 0.0% | ₹32 Cr 3.0% | ₹33 Cr 0.0% | ₹33 Cr |
| CWIP | ₹98 Cr 108.5% | ₹47 Cr 683.3% | ₹6 Cr 50.0% | ₹4 Cr 33.3% | ₹3 Cr 95.4% | ₹65 Cr 116.7% | ₹30 Cr 50.0% | ₹20 Cr 566.7% | ₹3 Cr 200.0% | ₹1 Cr |
| Investments | ₹77 Cr 6.9% | ₹72 Cr 0.0% | ₹72 Cr 16.1% | ₹62 Cr 12.7% | ₹71 Cr 18.3% | ₹60 Cr 15.4% | ₹52 Cr 1.9% | ₹53 Cr 5.4% | ₹56 Cr 5.7% | ₹53 Cr |
| Other Assets | ₹160 Cr 24.0% | ₹129 Cr 29.0% | ₹100 Cr 11.1% | ₹90 Cr 26.8% | ₹71 Cr 51.1% | ₹47 Cr 56.7% | ₹30 Cr 21.1% | ₹38 Cr 8.6% | ₹35 Cr 34.6% | ₹26 Cr |
| Total Assets | ₹399 Cr 27.5% | ₹313 Cr 30.4% | ₹240 Cr 9.1% | ₹220 Cr 4.8% | ₹210 Cr 3.4% | ₹203 Cr 42.0% | ₹143 Cr 0.7% | ₹144 Cr 12.5% | ₹128 Cr 13.3% | ₹113 Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹18 Cr 1000.0% | ₹-2 Cr 166.7% | ₹3 Cr 50.0% | ₹6 Cr 87.0% | ₹46 Cr 1050.0% | ₹4 Cr | ₹0 Cr 100.0% | ₹1 Cr 0.0% | ₹1 Cr 94.1% | ₹17 Cr |
| Investing CF | ₹-40 Cr 400.0% | ₹-8 Cr 200.0% | ₹8 Cr 153.3% | ₹-15 Cr 60.5% | ₹-38 Cr 280.0% | ₹-10 Cr 28.6% | ₹-14 Cr 250.0% | ₹-4 Cr 100.0% | ₹-2 Cr 90.0% | ₹-20 Cr |
| Financing CF | ₹13 Cr 44.4% | ₹9 Cr 1000.0% | ₹-1 Cr 114.3% | ₹7 Cr 250.0% | ₹2 Cr 100.0% | ₹1 Cr 94.1% | ₹17 Cr 183.3% | ₹6 Cr | ₹0 Cr | ₹0 Cr |
| Net Cash Flow | ₹-9 Cr 800.0% | ₹-1 Cr 110.0% | ₹10 Cr 600.0% | ₹-2 Cr 120.0% | ₹10 Cr 300.0% | ₹-5 Cr 266.7% | ₹3 Cr 50.0% | ₹2 Cr | ₹0 Cr 100.0% | ₹-2 Cr |
| Free Cash Flow | ₹-29 Cr 262.5% | ₹-8 Cr 700.0% | ₹-1 Cr 50.0% | ₹-2 Cr 122.2% | ₹9 Cr 250.0% | ₹-6 Cr 68.4% | ₹-19 Cr 850.0% | ₹-2 Cr | ₹0 Cr 100.0% | ₹-26 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 156d 4.7% | 149d 4.9% | 142d 7.6% | 132d 8.2% | 122d 11.9% | 109d 26.7% | 86d 41.9% | 148d 24.5% | 196d 31.5% | 286d |
| Inventory Days | 53d 194.4% | 18d 80.0% | 10d 64.3% | 28d 20.0% | 35d 50.0% | 70d 94.4% | 36d 7.7% | 39d 53.6% | 84d 23.6% | 110d |
| Days Payable | 189d 60.2% | 118d 41.0% | 200d 16.3% | 239d 54.5% | 525d 489.9% | 89d 169.7% | 33d 69.4% | 108d 41.3% | 184d 19.5% | 154d |
| Cash Conv. Cycle | 20d 60.0% | 50d 204.2% | -48d 39.2% | -79d 78.5% | -367d 512.4% | 89d 0.0% | 89d 12.7% | 79d 17.7% | 96d 60.2% | 241d |
| Working Capital Days | 56d 86.7% | 30d 850.0% | -4d 90.0% | -40d 82.1% | -223d 1113.6% | 22d 40.5% | 37d 60.2% | 93d 19.1% | 115d 50.9% | 234d |
| ROCE | 16.0% 23.1% | 13.0% 30.0% | 10.0% 66.7% | 6.0% 100.0% | 3.0% 200.0% | 1.0% 83.3% | 6.0% 20.0% | 5.0% 155.6% | -9.0% 10.0% | -10.0% |
Source: Screener.in · Lower days = better efficiency
About Kilitch Drugs (India) Limited
Incorporated in 1978, Kilitch Drugs Ltd is engaged in the operation and management of Pharmaceutical Products[1]
HealthcarePharmaceuticals & Biotechnology
Related Analysis
Frequently Asked Questions
What is Kilitch Drugs (India) Limited share price today?
Kilitch Drugs (India) Limited (KILITCH) is currently trading at ₹214.97 on NSE, up 3.59% as of the last market session. Prices update daily after market close on MarketNetra.
Is Kilitch Drugs (India) Limited available in F&O (Futures & Options)?
Yes, Kilitch Drugs (India) Limited (KILITCH) is part of the NSE F&O segment with a lot size of 1 shares. Options are available with monthly expiry contracts. You can track the full option chain and OI analysis on MarketNetra.
What is Kilitch Drugs (India) Limited 52-week high and low?
Kilitch Drugs (India) Limited's 52-week high is ₹267.9 and the 52-week low is ₹117. The current price of ₹214.97 is 19.8% below the 52W high.
What is Kilitch Drugs (India) Limited P/E ratio?
Kilitch Drugs (India) Limited's current P/E ratio is 25.4. This indicates the market is paying ₹25.4 for every ₹1 of earnings. Compare this to the sector average to assess relative valuation.
How to trade Kilitch Drugs (India) Limited options?
Kilitch Drugs (India) Limited options are traded on NSE with monthly expiry contracts (lot size: 1 shares). To trade KILITCH options: select your expiry on the option chain page, identify key OI strikes, check the PCR and buildup type on OI analysis, and review FII/DII flows for institutional sentiment before taking a position.